EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

TOP GLOVE CORPORATION BHD (BVA) fair value: what the stock is really worth

We calculate from audited financials what TOP GLOVE CORPORATION BHD is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SG · ISIN MYL7113OO003

TG TOP GLOVE CORPORATION BHD logo Thin data Sep 13, 2026

TOP GLOVE CORPORATION BHD

BVA · SG

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value 0.1200 SGD · Strongly overvalued (−53%)
!Quality 62/100
!Weak Growth (revenue 5y −13.6 %/yr)
!Thin margins · 4.8% net margin (TTM)
✓Low debt · generates free cash flow
·1.96% dividend yield
✓Ranks above peers (9/15)
!Narrow moat 33/100
!Evidence only low, so the estimate is less certain
!Weak on past: 15 out of 100
Watch TOP GLOVE CORPORATION BHD for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

1.42 SGD 0.1730 SGD Fair Value 0.1200 SGD Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range 0.1730 SGD – 1.42 SGD · fair‑value band 0.0800 SGD – 0.1400 SGD · the 0.2550 SGD price screens above the 0.1200 SGD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Top Glove Corporation Bhd., an investment holding company, engages in the manufacture, trade, and sale of gloves in Malaysia, Thailand, the People's Republic of China, and internationally.

Show more

Top Glove Corporation Bhd., an investment holding company, engages in the manufacture, trade, and sale of gloves in Malaysia, Thailand, the People's Republic of China, and internationally. It offers nitrile, latex, surgical, rubber, examination, medical, and vinyl gloves; concentrate and synthetic latex, formers, chemicals and chemical compounds, rubber dental dams, exercise bands, condoms, and rubber related products; packaging materials, boxes, and cartons; and disposable and medical face masks, engineering parts and rubber glove machinery, functional fillers, healthcare products, and home care and personal care products. The company also provides property investment and consultancy services, and electrical engineering works; clinical and specialist medical services; analytical, medical related consultancy, emergency medical, advisory, accommodation, management and trading, and value added services; financial and treasury services; management services in plantation sector; processing of plantation produce; and industrial forest plantation services, as well as forestry and industry services. In addition, it trades in healthcare related products; distributes medical devices and products; operates as a special purpose vehicle solely for issuance of Perpetual Sukuk; organizes in-house trainings and public trainings/programs; and establishes and maintains fitness related business, including healthcare, slimming centers, gymnasiums, and other related activities. Further, it generates and supplies energy and electricity using biomass technology; and offers e-commerce services for glove trading and other healthcare products. Additionally, the company provides gamma irradiation services for sterilization of gloves and medical devices; acts as an agent in the sale of various goods; wholesales pharmaceutical goods; and buys and sells real estate. Top Glove Corporation Bhd. was founded in 1991 and is headquartered in Shah Alam, Malaysia.

Stock analysis

TOP GLOVE CORPORATION BHD (BVA) currently trades at 0.2550 SGD, while our model-based Fair Value estimate is 0.1200 SGD, implying the stock looks roughly 112.5% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 0.4000 SGD per share, and 15 of the 26 models we run sit above the 0.2550 SGD price.

Bear case: the Economic Profit group reads lowest at 0.0600 SGD, and 11 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.0800 SGD (bear) to 0.1400 SGD (bull), the price of 0.2550 SGD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 62/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

TOP GLOVE CORPORATION BHD reported revenue of 3.5B MYR in FY2025 versus 16.4B MYR in FY2021, a compound −32.0%/yr. Reported net income was 128M MYR in FY2025, compounding −64.1%/yr from FY2021.

Key figures

Market cap 2.0B SGD (≈ $1.6B) · P/E ratio 25.5 · P/S ratio 0.94 · EPS (TTM) 0.0100 SGD · Dividend yield 2.0% · Net margin 3.7% · Return on equity 3.8% · Return on assets (EBIT) 18.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 48% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −53%, BVA screens richer than that median.

Fair Value models

Bear 0.0800 SGD Fair Value 0.1200 SGD Bull 0.1400 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (0.0050 SGD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 0.2300 SGD 0.3400 SGD 0.4800 SGD 80
Growth DCF 0.2300 SGD 0.3300 SGD 0.4600 SGD 79
Owner Earnings 0.4000 SGD 0.5900 SGD 0.8500 SGD 76
All 26 models by family
DCF Models
FCF DCF 0.2300 SGD 0.3400 SGD 0.4800 SGD 80
Owner Earnings 0.4000 SGD 0.5900 SGD 0.8500 SGD 76
5Y Revenue Exit 0.1300 SGD 0.1500 SGD 0.1800 SGD 74
5Y EBITDA Exit 0.3500 SGD 0.5800 SGD 0.8600 SGD 74
5Y P/E Exit 0.2600 SGD 0.4000 SGD 0.5600 SGD 71
10Y Revenue Exit 0.1700 SGD 0.2000 SGD 0.2400 SGD 68
10Y EBITDA Exit 0.3000 SGD 0.4800 SGD 0.7300 SGD 67
10Y P/E Exit 0.2500 SGD 0.3600 SGD 0.5200 SGD 64
Earnings-Based
Graham-Dodd 0.1100 SGD 0.4000 SGD 0.5400 SGD 64
Lynch FV 0.1000 SGD 0.1400 SGD 0.1800 SGD 61
PEG = 1.0 0.1000 SGD 0.1400 SGD 0.1800 SGD 57
EPV 0.0600 SGD 0.0600 SGD 0.0600 SGD 74
Dividend Discount
Gordon GGM 0.0500 SGD 0.0800 SGD 0.1100 SGD 68
DDM Multi-Stage 0.0500 SGD 0.0700 SGD 0.0900 SGD 67
Multiples
P/E Multiple 0.2600 SGD 0.3500 SGD 0.4400 SGD 63
P/S Multiple 0.2000 SGD 0.2700 SGD 0.3400 SGD 58
P/B Multiple 0.2000 SGD 0.2700 SGD 0.3400 SGD 55
EV/EBIT 0.0700 SGD 0.0800 SGD 0.1000 SGD 66
EV/EBITDA 0.4700 SGD 0.6100 SGD 0.7500 SGD 67
EV/Revenue 0.0600 SGD 0.0700 SGD 0.0800 SGD 54
Asset-Based
NCAV (Graham) 0.3000 SGD 0.4000 SGD 0.5900 SGD 54
Growth DCF
Growth DCF 0.2300 SGD 0.3300 SGD 0.4600 SGD 79
Rev-Margin DCF 0.1300 SGD 0.1600 SGD 0.1900 SGD 74
Economic Profit
Residual Income 0.4000 SGD 0.3800 SGD 0.2900 SGD 76
ROIC Compounder 0.0600 SGD 0.0600 SGD 0.0600 SGD 72
Growth Earnings
Growth-Adj P/E 0.1800 SGD 0.2600 SGD 0.3400 SGD 67

Open the full fair value analysis →

Notify me when BVA reaches fair value

Put BVA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 62/100

Of which business quality 59 · Market factors (momentum, volatility) 66

Profitability 25
Margins and returns on capital today
Quality Growth 72
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 58
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 63
Calm price path (market factor)
Momentum 63
Price trend over the last 3–12 months (market factor)
52W Momentum 76
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+38.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.6%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
30.4% (2020) → 0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.9%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)+13.6%
Forecast 2027 (sales)+13.6%
Projected 2028 (sales)+12.2%
Projected 2029 (sales)+10.7%
Projected 2030 (sales)+9.3%

BVA screens 112% overvalued. Compare with Intuitive Surgical, Inc →

Compare TOP GLOVE CORPORATION BHD with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 200 stocks

Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 62 · Above median
Fair Value upside −45% · Below median
Profitability
Return on equity (TTM) 4% · Below median
Return on assets 1% · Below median
Net margin (TTM) 5% · Below median
Operating margin (TTM) 14% · Above median
Growth and dividend
Revenue growth 32% · Top 25%
Dividend yield (TTM) 2.0% · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 25.5× · Pricier than median
P/B 0.29× · Cheapest 25%
P/S (TTM) 0.35× · Cheapest 25%
P/FCF 8.4× · Pricier than median
EV/EBITDA 2.4× · Cheapest 25%
PEG 0.07× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 24
PAST (return on equity)15 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)39 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $369.15 $350.02 −5%
EssilorLuxottica Société anonyme EL €146.40 €161.04 +10%
Medline Inc MDLN $32.53 $11.80 −64%
Becton, Dickinson and Company BDX $177.85 $100.46 −44%
Alcon Inc ALC $66.03 $39.78 −40%
ResMed Inc RMD A$30.31 A$33.34 +10%
West Pharmaceutical Services, Inc WST $346.23 $137.28 −60%
Sartorius Stedim Biotech S.A DIM €186.90 €48.88 −74%
Straumann Holding STMN CHF 94.10 CHF 45.50 −52%
Sartorius Aktiengesellschaft SRT3 €232.90 €42.05 −82%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

TOP GLOVE CORPORATION BHD · Fair Value
0.1200 SGD −112%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "TOP GLOVE CORPORATION BHD Fair Value". https://www.fairvalue-calculator.com/stock/BVA

Frequently asked questions

Is TOP GLOVE CORPORATION BHD (BVA) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 0.1200 SGD versus a price of 0.2550 SGD, about −53% upside (overvalued).
What is the fair value of BVA?
Our model-based fair value for TOP GLOVE CORPORATION BHD is 0.1200 SGD (as of Sep 13, 2026), built from audited fundamentals. The current price: 0.2550 SGD.
What is the quality score of BVA?
TOP GLOVE CORPORATION BHD has a Quality Score of 62/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TOP GLOVE CORPORATION BHD (BVA)?
Our model-based price target is the fair value of 0.1200 SGD (as of Sep 13, 2026) from 26 valuation models. Cautious scenario 0.0800 SGD, optimistic scenario 0.1400 SGD. It is a calculation from audited fundamentals, not an analyst target.
What is the TOP GLOVE CORPORATION BHD stock forecast for 2026?
Our models put fair value at 0.1200 SGD, about −53% upside versus a price of 0.2550 SGD (overvalued). Cautious scenario 0.0800 SGD, optimistic scenario 0.1400 SGD. The calculation is refreshed regularly with new filings.
What is the revenue of TOP GLOVE CORPORATION BHD (BVA)?
TOP GLOVE CORPORATION BHD reported trailing-twelve-month revenue of about 3.9B SGD (latest available figure, as of Sep 13, 2026).
Does TOP GLOVE CORPORATION BHD pay a dividend?
TOP GLOVE CORPORATION BHD currently shows a dividend yield of about 1.96% relative to its recent price (as of Sep 13, 2026).
What growth is priced into TOP GLOVE CORPORATION BHD (BVA)?
For today's price to be fair in a discounted-cash-flow model, TOP GLOVE CORPORATION BHD would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.6 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of BVA use?
Our models discount TOP GLOVE CORPORATION BHD at 9.6 %: a base by market capitalisation (small), damped by beta 0.45, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TOP GLOVE CORPORATION BHD that is less than minus 40 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has TOP GLOVE CORPORATION BHD (BVA) delivered so far?
Over the past 5 years revenue at TOP GLOVE CORPORATION BHD grew -13.6 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TOP GLOVE CORPORATION BHD (BVA) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into TOP GLOVE CORPORATION BHD (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TOP GLOVE CORPORATION BHD (BVA)?
The free-cash-flow yield on the price is 7.92 %: that much free cash flow TOP GLOVE CORPORATION BHD produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TOP GLOVE CORPORATION BHD (BVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TOP GLOVE CORPORATION BHD it is 0.1200 SGD per share (as of Sep 13, 2026), against a price of 0.2550 SGD. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is TOP GLOVE CORPORATION BHD stock overvalued or undervalued in 2026?
As of Sep 13, 2026, BVA trades above its calculated fair value: price 0.2550 SGD, fair value 0.1200 SGD, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BVA?
No. The price is what the market pays today (0.2550 SGD); the fair value is what the company's own numbers justify (0.1200 SGD). For TOP GLOVE CORPORATION BHD the two are 0.1350 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is TOP GLOVE CORPORATION BHD worth?
The market values TOP GLOVE CORPORATION BHD at about 2.0B SGD (market capitalisation, as of Sep 13, 2026). Per share that is 0.2550 SGD; our models calculate a fair value of 0.1200 SGD per share.
What do the bullish and bearish scenarios say about BVA?
Our models span a range for TOP GLOVE CORPORATION BHD: cautious scenario 0.0800 SGD, base 0.1200 SGD, optimistic 0.1400 SGD per share (as of Sep 13, 2026, price 0.2550 SGD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BVA?
TOP GLOVE CORPORATION BHD trades at a price-to-earnings ratio of 25.5 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.1200 SGD is built from several models across several years. Other multiples: PEG 0.1, P/B 0.3, P/S 0.4, EV/EBITDA 2.4.
What is the PEG ratio of BVA?
The PEG ratio of TOP GLOVE CORPORATION BHD is 0.07 (P/E divided by earnings growth, as of Sep 13, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of TOP GLOVE CORPORATION BHD (BVA)?
Balance-sheet figures for TOP GLOVE CORPORATION BHD (as of Sep 13, 2026): return on equity 3.8%. They feed the Quality Score of 62/100, which measures business quality independently of the share price.
How far is BVA from its 52-week high?
TOP GLOVE CORPORATION BHD trades at 0.2550 SGD, about 11% below its 52-week high of 0.2850 SGD and 48% above the low of 0.1720 SGD (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1200 SGD is for.
Which stocks are comparable to TOP GLOVE CORPORATION BHD?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TOP GLOVE CORPORATION BHD stock attractive at the current price?
The data as of Sep 13, 2026: price 0.2550 SGD, calculated fair value 0.1200 SGD (−53%), Quality Score 62/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BVA calculated?
We run TOP GLOVE CORPORATION BHD through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.1200 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. TOP GLOVE CORPORATION BHD itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TOP GLOVE CORPORATION BHD (BVA)?
The closing price on Sep 14, 2026 was 0.2550 SGD. Our model-based fair value is 0.1200 SGD, about −53% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TOP GLOVE CORPORATION BHD right now?
The price sits above even our optimistic bull case (0.1400 SGD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (62/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of TOP GLOVE CORPORATION BHD

How large is the market capitalisation of TOP GLOVE CORPORATION BHD (BVA)?
The market capitalisation of TOP GLOVE CORPORATION BHD is 2.0B SGD (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TOP GLOVE CORPORATION BHD (BVA)?
The price-to-sales ratio of TOP GLOVE CORPORATION BHD is 0.94 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TOP GLOVE CORPORATION BHD (BVA)?
Earnings per share at TOP GLOVE CORPORATION BHD are 0.0100 SGD (price ÷ EPS = P/E 25.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of TOP GLOVE CORPORATION BHD (BVA)?
The dividend yield of TOP GLOVE CORPORATION BHD is 2.0% (payout 50.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of TOP GLOVE CORPORATION BHD (BVA)?
The net margin of TOP GLOVE CORPORATION BHD is 3.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TOP GLOVE CORPORATION BHD (BVA)?
The return on equity (ROE) of TOP GLOVE CORPORATION BHD is 3.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TOP GLOVE CORPORATION BHD (BVA)?
On an EBIT basis the return on assets of TOP GLOVE CORPORATION BHD is 18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TOP GLOVE CORPORATION BHD (BVA)?
The operating margin of TOP GLOVE CORPORATION BHD is 13.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TOP GLOVE CORPORATION BHD (BVA)?
Revenue at TOP GLOVE CORPORATION BHD is growing +31.9% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TOP GLOVE CORPORATION BHD (BVA)?
Earnings per share at TOP GLOVE CORPORATION BHD are growing +135% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does TOP GLOVE CORPORATION BHD (BVA) carry?
The net debt of TOP GLOVE CORPORATION BHD is 532M SGD (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch TOP GLOVE CORPORATION BHD in the live analysis

One click puts TOP GLOVE CORPORATION BHD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.